How I Identify and Treat MF Patients With Ruxolitinib Failure


Upon viewing this session, you will be able to:
• Define ruxolitinib failure
• Identify appropriate patients with myelofibrosis in need of second line or JAK inhibitor combination therapy
• Recognize patients receiving ruxolitinib that should proceed to hematopoietic stem cell transplantation
• Summarize investigational approaches for patients who fail ruxolitinib therapy


  • John Mascarenhas, MD, Mount Sinai School of Medicine


Member Type Price
List Price $30.00
Active, International, Emeritus, and Honorary Members $20.00
Associate, International Associate, Student, and Resident Members $20.00
back to top